Evidence map›Paper›PMID 26874946›Full record

Trial reportHeart and vessels2016

Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.

Yanming Fan, Qingmin Wei, Junna Cai, Yongtang Shi, Youliang Zhang, Limei Yao, Xiaogang Wang, Shupo Lin, Yilin Li, Jing Lv and 2 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Heart and vessels, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 7 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 7 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yanming FanDepartment of Cardiology, Xingtai People's Hospital, Xingtai, 054000, China.
Qingmin WeiDepartment of Cardiology, Xingtai People's Hospital, Xingtai, 054000, China. weiqingmin@medmail.com.cn.
Junna CaiDepartment of Cardiology, Xingtai People's Hospital, Xingtai, 054000, China.
Yongtang ShiDepartment of Cardiology, Xingtai People's Hospital, Xingtai, 054000, China.
Youliang ZhangDepartment of Cardiology, Xingtai People's Hospital, Xingtai, 054000, China.
Limei YaoDepartment of Cardiology, Xingtai People's Hospital, Xingtai, 054000, China.
Xiaogang WangDepartment of Cardiology, Xingtai People's Hospital, Xingtai, 054000, China.
Shupo LinDepartment of Cardiology, Xingtai People's Hospital, Xingtai, 054000, China.
Yilin LiDepartment of Cardiology, Xingtai People's Hospital, Xingtai, 054000, China.
Jing LvDepartment of Cardiology, Xingtai People's Hospital, Xingtai, 054000, China.
Bin ZhouDepartment of Cardiology, Xingtai People's Hospital, Xingtai, 054000, China.
Ruijuan DuDepartment of Cardiology, Xingtai People's Hospital, Xingtai, 054000, China.
Hebei Medical University · CNXingtai People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to investigate the preventive effect of oral nicorandil on contrast-induced nephropathy (CIN) in patients with renal insufficiency undergoing elective cardiac catheterization. A total of 240 patients with an estimated glomerular filtration rate (eGFR) of 60 mL/min or less, who were undergoing elective cardiac catheterization, were randomly assigned to nicorandil group (n = 120, 10 mg nicorandil, three times daily from 2 days before to 3 days after procedure) or control group (n = 120, matching placebo as the same method). The primary endpoint was the incidence of CIN defined as 25 % increase in serum creatinine (SCr) from baseline or 44 μmol/L (0.5 mg/dL) increase in absolute value within 72 h after exposure to contrast medium. The secondary endpoints were: (1) the changes of SCr, Cystatin-C (Cys-C) and eGFR within 72 h; (2) major adverse events (MACE) occurring within 30 days. Baseline characteristics of the patients in the two groups were similar. The incidence of CIN was significantly lower in nicorandil group compared with control group (6.67 vs. 17.5 %, P = 0.017). Compared with the control group, nicorandil group tended to have a lower SCr and Cys-C levels as well as a higher eGFR at 48 h after the procedure (all P < 0.05). There was no difference about the incidence of MACE within 30 days between nicorandil group and control group (4.16 vs. 5.83 %, P = 0.767). Multivariate logistic analysis showed that nicorandil was an independent protective factor against CIN (OR = 0.260, 95 % CI = 0.1-0.676, P = 0.006). Therefore, we concluded that oral nicorandil was associated with a decline in the incidence of CIN in patients with renal insufficiency undergoing elective cardiac catheterization.

Indexed as

Administration, OralAgedBiomarkersCardiac CatheterizationChinaChi-Square DistributionContrast MediaCoronary AngiographyCreatinineDouble-Blind MethodFemaleGlomerular Filtration RateHumansIohexolKidneyKidney DiseasesBiomarkersContrast MediaCreatinineIohexoliopromideNicorandilProtective AgentsCardiac catheterizationContrast-induced nephropathyNicorandilRenal insufficiency

Identifiers

PMID26874946
OpenAlexW2256639800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.